Compare FRD & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRD | CDXS |
|---|---|---|
| Founded | 1965 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Major Chemicals |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.2M | 141.8M |
| IPO Year | N/A | 2010 |
| Metric | FRD | CDXS |
|---|---|---|
| Price | $20.40 | $1.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.3K | ★ 925.3K |
| Earning Date | 02-06-2026 | 02-26-2026 |
| Dividend Yield | ★ 0.78% | N/A |
| EPS Growth | ★ 43.48 | N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $510,450,000.00 | $52,932,000.00 |
| Revenue This Year | N/A | $15.64 |
| Revenue Next Year | N/A | $5.23 |
| P/E Ratio | $12.61 | ★ N/A |
| Revenue Growth | ★ 8.72 | N/A |
| 52 Week Low | $12.24 | $1.22 |
| 52 Week High | $23.50 | $4.51 |
| Indicator | FRD | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 57.02 | 37.26 |
| Support Level | $18.25 | $1.22 |
| Resistance Level | $19.95 | $1.48 |
| Average True Range (ATR) | 0.82 | 0.14 |
| MACD | 0.17 | -0.03 |
| Stochastic Oscillator | 85.38 | 10.53 |
Friedman Industries Inc is engaged in the manufacturing and processing of steel products. The company's operating segments include flat-roll products and Tubular Products. It generates maximum revenue from the flat-roll products segment. The company's products and services include Temper Pass, Cut-To-Length, Whole Coils, Toll Processing, Electric Resistance Welded Pipe (ERW), New Mill Secondary, and Pipe Finishing Services.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.